

Index

- access and benefit sharing 114–20, 122
- activism *see* treaty interpretation
- advanced informed agreement 107
- agriculture
 - conventional 3, 6–8, 10, 35, 44, 106, 110–11, 175–6
 - genetically modified 5–10, 19, 35–6, 44, 106, 110–11, 120–21, 176
 - organic 44, 110–11
- Artavia Murillo v Costa Rica* 21–2, 26, 30, 58–9, 60, 80–81, 176
- Association for Molecular Pathology v Myriad Genetics* 161–3
- Bablok v Bayern* 43–4, 110–11, 126
- benefit sharing 114–15, 119–23
- biocolonialism 114
- biological resources
 - diversity of 105–7
 - and rights of indigenous peoples 121–4
- biomedical research 53, 56, 63–4, 67–8, 71–2, 77, 176
- biopiracy 114
- biotechnological inventions
 - and EU law 85–6, 153, 156–60
 - patents on 5, 85–6, 118, 156–72, 174
- biotechnology
 - blue 15
 - green 5–10, 18
 - grey 5, 15
 - red 5, 10–13
 - white 5, 14–15
- Bowman v Monsanto* 147
- Brincat v Malta* 61
- Brüstle v Greenpeace* 29, 86, 170–72
- Canada – Continued Suspension* 135, 138
- Cas9 1–2, 9, 11, 45, 47–8
- CETA 103, 126, 144–5
- China – Publications* 131
- CIOMS 68, 70, 90
- cloning
 - animal cloning 148, 160–61
 - Dolly the sheep 3, 95, 160–61
 - human cloning 1, 4, 20, 92, 95–9
 - reproductive cloning 28, 55–6, 96–9
 - therapeutic cloning 11, 28, 96–9, 175
- Colombia – Textiles* 132
- Commission v Germany* 177
- compulsory licensing 147, 152–6
- Confédération paysanne v Premier ministre* 45–6, 102
- consent
 - community consent 69–71
 - informed consent 62, 66–70, 87, 95, 116, 119
- consistency 21–5, 30–31, 36, 84
- Convention on Biological Diversity 102–3, 105–7, 114–15, 119–20, 134
- Costa and Pavan v Italy* 13, 23–4, 31
- CRISPR 1–3, 9, 11, 45–8
- cross-pollination 43–4, 106, 110
- CPTTP 126, 144–6
- Danish Council of Ethics 2–3

- D'Arcy v Myriad Genetics* 162
- Decision 391 (Andean Community) 114
- democratic choices 174
- Diamond v Chakrabarty* 158, 166
- Directive 98/44/EC 85–6, 118, 149–51, 156–8, 163, 166–7, 169–70
- discrimination
 - prohibition of 76–8
 - in trade law *see* GATT; most-favoured nation treatment; national treatment; SPS Agreement
- DNA sequences
 - patentability *see* patents
- Doctors' Trial* 62–3, 66
- EC – Asbestos* 128
- EC – Biotech* 41, 126, 134–6, 138–41
- EC – Hormones* 135, 138–9
- EC – Seal Products* 25, 131–2
- embryo
 - use of 28–9, 82–8, 148, 169–72, 175
- environmental protection 15, 25, 101–5, 107, 125, 127, 129–30, 136, 151
- equality
 - in the access to biotechnology 77–8
 - non-discrimination, human rights 75–7
- essentially biological process *see* patents
- ethics
 - bioethics, international standards 26–9
 - ethical standards 17–18, 131–2, 174
 - ethical values 17–18, 22–6
- European Patent Convention 149, 157–8, 159–60
- Evans v United Kingdom* 175
- family life, right to 24, 30, 51, 61, 71, 73–5
- FAO Seed Treaty 120–21
- FDA 7, 33, 89, 92
- food
 - right to 52, 64–5
 - food security 64–5, 120
- GATS 127
- GATT
 - general exceptions 25, 130–34
 - non-discrimination obligations 126–30
 - public health exception 132–4
 - public morals exception 127, 130–33
- gene flow *see* cross-pollination
- gene therapy 10–13, 19, 32, 88–95, 174
- genetic data
- genetic testing 53, 56, 67, 72, 74–5, 77, 90
 - collection of 66, 69–71
- genetic engineering 1–2, 6–10, 19, 32, 34–48, 57, 96, 130–31, 156, 174
- genome editing 1–2, 6, 9–12, 45–8
- germline intervention 88–95
- GINA 75
- GMOs 8, 32, 35–7, 38, 40–50, 101, 103, 105, 107, 110–11, 126–29, 134, 141, 147
- golden rice 7–8
- Gómez Murillo v Costa Rica* 59–60
- health
 - exception in trade law *see* GATT; *see also* right to health 51–2, 60–65, 153
- HIV / Aids 154
- honey case *see* *Bablok v Bayern*
- human dignity 12, 17, 21, 28–30, 51–2, 54–8, 67, 77–8, 82, 85–6, 96, 148, 157, 170–71, 174, 176
- Human Fertilisation and Embryology Authority (UK) 81–2, 92
- Human Genome Diversity Project 69–70

- human rights 3–4, 17–18, 28–30, 51–79, 82, 104, 123–4, 148, 174–7
- imago Dei* 17–18, 175
- In Re Dane K. Fisher v Lalgudi* 163
- In Re Roslin Institute* 160
- in vitro* fertilization 1, 12–14, 18–31, 45, 52, 58–60, 80–6, 89, 92, 98–9, 148, 170–71, 175
- indigenous communities 35, 49, 71, 108, 114, 119, 121–4, 134, 172
- Indonesia – Horticultural Products* 131, 133
- industrial processes 14–15
- inter-generational ethics 104–5
- International Covenant on Civil and Political Rights 51, 66, 71, 73, 76
- International Covenant on Economic, Social and Cultural Rights 52, 61, 64, 76, 148, 153
- International Stem Cell Research Corp. v Comptroller General* 86, 171–2
- I.V. v Bolivia* 61, 64
- Japan – Apples* 137
- Kingdom of the Netherlands v European Parliament* 118, 156–7, 170
- Knecht v Romania* 175–6
- Korea – Radionuclides* 138
- Kudla v Poland* 61
- Land Oberösterreich v Commission* 111
- life
- right to 21–2, 26, 51–2, 57–60, 61–4, 85, 104
- living modified organisms 3, 49, 103, 105, 107–10, 134
- marine resources 15
- maternal spindle transfer 93
- Monsanto v Cefetra* 167
- Monsanto v Ministre de l'Agriculture* 41
- most-favoured nation treatment 126–8, 141, 150
- mutagenesis 6, 45–6
- mutually agreed terms 116–17, 122
- Nagoya Protocol on Access and Benefit Sharing 114, 119–20, 122–3
- Nagoya–Kuala Lumpur Protocol on Liability and Redress 109–10
- national treatment 126–8, 141–2, 145, 150
- Nuremberg Code 62–3, 66
- one door, one key 41
- Oviedo Convention 18, 28, 52–5, 58, 63–4, 66–8, 71–2, 74, 76, 86, 91, 97
- Parrillo v Italy* 176
- patents
- on DNA sequences 149, 161–7
 - essentially biological process 151, 159, 167–68
 - ethical aspects 168–72
 - functional limitation 166–7
 - on living organisms 158–61
 - on traditional knowledge 172
- Paton v United Kingdom* 57
- personal autonomy 17, 51, 66–71
- plant genetic resources 115–16, 120–21
- poisonous tree 85, 115, 171
- precautionary principle 4, 34–5, 41, 46, 102–5, 108, 138–9
- preimplantation diagnosis 13, 18, 20, 24, 81, 175
- Pretty v United Kingdom* 54
- privacy
- right to 51, 63, 71–3, 75, 104, 148
- pro-nuclear transfer 94
- proportionality 21–6, 132
- public morals
- and patents 148, 151, 159–60, 168–71

- exception *see* GATT
- morality 30, 86
- Pulp Mills Case* 101, 104–5
- Quintavalle v HFEA* 81–2
- rationality 22–6, 174
- regulation
 - of genetic engineering 37–50
 - horizontal approach 40–44
 - process approach 40–44
 - product approach 38–40
 - and socio-economic considerations 49–50
 - vertical approach 38–40,
- religion 18–22, 25–6, 54, 60, 131, 174–5
- reproductive medicine 12–14, 80–82, 175
- research
 - on human embryos 11–13, 18–20, 28–31, 57–8, 63, 82–8, 91–4, 97–99, 148, 169–72, 175
 - on human subjects 54–7, 62–4, 66–73
 - stem cell research 11–14, 18–20, 26, 28–9, 55, 82–8, 97, 170–72, 174–5
- risk
 - assessment of 4–5, 27, 32–8, 49–50, 102–3, 107–9, 125, 127, 129, 133–4, 133–5, 137–8, 144–6, 177
 - management of 4–5, 32–7, 45, 47, 108
 - perception of 21, 27–8, 32–7, 133, 174–5
- Roche v Roche* 84
- R.R. v Poland* 25
- sanitary measures *see* SPS
- Saramaka People v Suriname* 123–4
- saviour sibling 81
- scientific evidence
 - requirement in trade law *see* SPS
 - self-determination
 - individual right to 66–71
 - S.H. and Others v Austria* 24–5, 175
 - SPS
 - non-discrimination obligation 128, 139
 - precaution *see* precautionary principle
 - procedural requirements 140
 - scientific evidence requirement 137–9
 - standard material transfer agreement 121
 - substantial equivalence 38–9, 128
 - Tătar v Romania* 61, 104
 - TBT 126, 140–43
 - test tube baby *see in vitro* fertilization
 - traditional knowledge 114, 118–20, 122–3, 172
 - Trail Smelter Case* 101
 - treaty interpretation
 - judicial activism 26, 30–31, 176
 - TRIPS 5, 118, 127, 149, 150–57, 159, 168–9, 171–2
 - UPOV Convention 149–50
 - US – Animals* 137–8
 - US – Clove Cigarettes* 142
 - US – COOL* 141–3
 - US – Gambling* 131–2
 - US – Gasoline* 130
 - US – Poultry* 134, 139
 - US – Shrimp* 131
 - US – Tuna* 143
 - US – Tuna II (Mexico)* 141
 - values
 - ethical values *see* ethics
 - legal values 17–18, 22–6
 - socio-culturally entrenched values 26–9
 - value judgments 26
 - Vo v France* 57–8